Nivolumab + Relatlimab Continues Clinical Benefit in Advanced Melanoma

Source: Oncology times, April 2022

The combination of nivolumab and relatlimab continues to demonstrate a progression-free survival (PFS) benefit compared to nivolumab alone in patients with previously untreated metastatic or unresectable melanoma. In addition, for the first time, the dual checkpoint inhibitor therapy also demonstrated a higher overall response rate (ORR), according to follow-up data from the RELATIVITY-047 trial.

Previously, the RELATIVITY-047, a global, randomized, double-blind, Phase II/III study, had met its primary endpoint of PFS after 13.2 months follow-up (J Clin Oncol 2021; doi: 10.1200/JCO.2021.39.15_suppl.9503). Relatlimab, a human LAG-3 blocking antibody, and nivolumab, an anti-PD-1 agent, as a fixed-dose combination demonstrated a significant PFS benefit, with a median PFS of 10.1 months with the combination versus 4.6 months with nivolumab monotherapy, with a manageable safety profile.

At an American Society of Clinical Oncology (ASCO) Plenary Series session in March 2022, lead author Georgina V. Long, MD, FRACP, PhD, Chair of Melanoma Medical Oncology and Translational Research at the Melanoma Institute Australia at the University of Sydney, presented updated PFS results and the first disclosure of secondary endpoints, including overall survival (OS) and ORR